Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD0-H525a | Human | Human CD40 / TNFRSF5 Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
TN5-H82F9 | Human | Biotinylated Human CD40 / TNFRSF5 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CD0-H82E8 | Human | Biotinylated Human CD40 / TNFRSF5 Protein, Avitag™,His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CD0-C52H6 | Cynomolgus | Cynomolgus CD40 / TNFRSF5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
TN5-M52H8 | Mouse | Mouse CD40 / TNFRSF5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
TN5-M5259 | Mouse | Mouse CD40 / TNFRSF5 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD0-C5259 | Rhesus macaque | Rhesus macaque CD40 / TNFRSF5 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD0-C52H7 | Rhesus macaque | Rhesus macaque CD40 / TNFRSF5 Protein, His Tag | ![]() |
![]() ![]() |
|
CD0-H5228 | Human | Human CD40 / TNFRSF5 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
CD0-H5253 | Human | Human CD40 / TNFRSF5 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
FACS analysis shows that Human CD40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD0-H525a) can bind to 293T cells overexpressing human CD40L. The concentration of Human CD40 is 0.03 μg/ml (Routinely tested).
Loaded Human CD40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD0-H525a) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.911 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Rhesus macaque CD40, Fc Tag (Cat. No. CD0-C5259) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.829 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
ISF-35 | Ad-CD154; Ad-ISF35; ISF-35 | Phase Ⅱ | Memgen LLC | Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) | Details |
MEDI-5083 | MEDI-5083,MEDI 5083,MEDI5083 | Phase Ⅰ | MedImmune, AstraZeneca | Solid tumours | Details |
APX-005M | APX-005; APX-005M; EPI-0050,APX005; APX005M; EPI0050 | Phase Ⅱ | Epitomics, Apexigen | Glioma, Non small cell lung cancer (NSCLC), Gastric cancer, Brain cancer, Renal cell carcinoma, Esophagus cancer, Solid tumours, Pancreatic cancer, Melanoma | Details |
FFP-104 | FFP-104 | Phase Ⅱ | FF Pharma | Crohn's disease, Primary biliary cirrhosis (PBC) | Details |
CDX-1140 | CDX-1140,CDX1140; CDX 1140 | Phase Ⅱ | Celldex | Melanoma | Details |
Bleselumab | 4D-11; ASKP-1240 | Phase Ⅱ | Kyowa Hakko Kogyo, Astellas | Transplant rejection | Details |
NJA-730 | NJA-730,NJA730,NJA 730 | Phase Ⅰ | NapaJen Pharma | Graft versus host disease | Details |
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) | Phase Ⅰ | Baylor College of Medicine | Chronic lymphocytic leukemia (CLL) | Details | |
ONCOS-401 | ONCOS-401 | Preclinical | Targovax | Solid tumours | Details |
BMS-986090 | BMS-986090; Anti-CD40-dab,BMS986090 | Phase Ⅰ | Bristol-Myers Squibb | Immunological disorders | Details |
Anti-CD40 ChiLob7/4 (BioNTech) | Phase Ⅱ | BioNTech | Head and neck cancer, Pancreatic cancer | Details | |
Iscalimab | CFZ-533; NVP-CFZ533; OM11-62-MF | Phase Ⅱ | Novartis | Myasthenia gravis, Lupus nephritis, Sjoegren's syndrome, Systemic lupus erythematosus, Graves' disease, Rejection of renal transplantation | Details |
TNX 100 | TNX-100 | Phase Ⅰ | Chiron, Tanox | Autoimmune diseases, Transplant rejection, Crohn's disease | Details |
Mitazalimab | ADC-1013; JNJ-7107; JNJ-64457107 | Phase Ⅰ | Alligator Bioscience, Janssen | Solid tumours | Details |
Lucatumumab | CHIR-12.12; HCD-122 | Phase Ⅱ | Novartis, Xoma | Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Multiple myeloma (MM), Lymphoma | Details |
CD40L-GVAX | CD40L-GVAX; GM-CSF/CD40L; GM.CD40L; hCD40L/hGM-CSF | Phase Ⅱ | University of South Florida, Cellular Biomedicine Group | Lung cancer, Melanoma | Details |
FFP-102 | PG-102; 5-D12 | Phase Ⅱ | PanGenetics, FF Pharma | Psoriatic arthritis, Crohn's disease | Details |
BI-655064 | BI-655064 | Phase Ⅱ | Boehringer Ingelheim, Abbvie | Lupus nephritis, Immune thrombocytopenic purpura, Rheumatoid arthritis (RA) | Details |
Ravagalimab | ABBV-323; PR-1629977 | Phase Ⅱ | Abbvie | Ulcerative colitis | Details |
SEA-CD40 | SEA-CD40 | Phase Ⅰ | Seattle Genetics | Solid tumours, Lymphoma | Details |
Dacetuzumab | PRO-64553; RG-3636; SGN-14; SGN-40; hu-S2C6,huS2C6 | Phase Ⅱ | Seattle Genetics | Diffuse large B cell lymphoma | Details |
Selicrelumab | RG-7876; RO-7009789 | Phase Ⅰ | Roche | Solid tumours, Non-Hodgkin's lymphoma (NHL), Pancreatic cancer | Details |
Teneliximab | BMS-224819 | Phase Ⅱ | Bristol-Myers Squibb | Transplant rejection, Rheumatoid arthritis (RA) | Details |
CP-870893 | CP-870893 | Phase Ⅰ | Pfizer, National Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute | Melanoma | Details |
CD40 ligand (Celldex Therapeutics) | Preclinical | Amgen, Celldex | Viral infections, Solid tumours, Non-Hodgkin's lymphoma (NHL), Immunological disorders, Renal carcinoma, Head and neck cancer, Cancer | Details | |
SHR-1704 | SHR-1704 | Phase Ⅰ | Jiangsu Hengrui Medicine | Solid tumours, Haematological disorders | Details |
AT-1501 | AT-1501 | Phase Ⅱ | ALS Therapy Development Institute, Anelixis Therapeutics | Amyotrophic lateral sclerosis (ALS) | Details |
This web search service is supported by Google Inc.